Based on Zuma-7 Studies CAR T-Cell Therapy Is Now Standard Treatment for B-Cell Lymphoma in Scandinavia

At ASH 2023, the ZUMA-7 trial about CAR T-cell therapy was presented as a second-line treatment for elderly patients with relapsed large B-cell lymphoma. In this MEDtalk from ASH 2024, Mats Jerkeman explains that there have been no updates since last year. Still, it is now standard treatment for early relapses in Scandinavian countries, and ongoing trials are exploring bispecific antibodies that could improve first-line treatment outcomes in the future.